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Background: The association between hyperemesis gravidarum (HG) and abnormal thyroid function is well known.
Aims: The prevalence, aetiology and course of thyrotoxicosis in women with hyperemesis gravidarum (HG) were studied.
Methods: Women admitted for HG, who underwent thyroid function evaluation between 1 August 2016 and 30 April 2019,
were studied. Laboratory data included baseline human chorionic gonadotropin (hCG) and baseline (t1), discharge (t2) and
follow-up (t3) thyroid function tests (thyroid stimulating hormone [TSH] and free thyroxin [fT4]). Available TSH receptor
antibody status was assessed.
Results: Eighty-two patients were included. The incidence of thyrotoxicosis was 49% based on local laboratory TSH range and
48% if trimester-specific ranges used. In the majority of normal pregnancies, thyrotoxicosis was hCG-mediated (72.5%), 15%
were confirmed to have Graves’ disease and 12% had a molar pregnancy. Very high fT4 levels (> 40 pmol/l) at baseline [t1]
were documented in 24% of women with hCG-mediated thyrotoxicosis. Clinical features were absent in a third of women
with Graves’ disease and the diagnosis was reliant on positive antibody status. Free T4 values declined from (t1) to later in
gestation (t3) (p < 0.001).
Conclusion: The incidence of thyrotoxicosis in women with HG is high. Free-T4 values decrease with clinical stabilisation of HG,
suggesting a contribution of dehydration to the large variation in baseline fT4 measurements. Testing for TSH-receptor
antibodies should be considered in women with TSH < 0.01 pmol/l and persistent fT4 elevation on follow-up. Final review
of thyroid function should be performed after 15 weeks’ gestation.
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Introduction
Nausea and vomiting in pregnancy have been documented
throughout history. Medical literature cites Antoine Dubois, a
consultant surgeon and a head obstetrician to Napoleon Bona-
parte and his second wife Empress Marie Louise, as the first
physician to describe the condition in 1852. Dubois described
the syndrome as a ‘pernicious vomiting of pregnancy’ and the
aetiology was unknown, but hypothesised to be due to ‘irri-
tation of the vomiting reflex from the stretching of the
uterine fibres,’ and ‘irritation of the cervix’.1 Since then, hyper-
emesis gravidarum has been increasingly recognised as an
important cause of maternal and foetal morbidity and even
mortality.
Hyperemesis gravidarum (HG) is intractable vomiting during
pregnancy associated with dehydration, electrolyte and/or
metabolic disturbances as well as weight loss of > 5% often
resulting in severe ketonuria, haemoconcentration and electro-
lyte and liver enzyme derangements.2 This condition represents
the extreme of nausea and vomiting encountered during preg-
nancy and is reported to occur in only 0.1–0.2% of pregnancies,
but remains a common reason for hospitalisation in the first half
of pregnancy, second only to pre-term labour.1,3 In South Africa
the incidence of HG is uncertain; however, in-hospital maternal
deaths attributable to HG have been reported.4
Human chorionic gonadotropin (hCG) is produced by placental
trophoblasts and part of the glycoprotein hormone family,
together with luteinising hormone (LH), follicle-stimulating
hormone (FSH) and thyroid-stimulating hormone (TSH). These
hormones are heterodimers that share a common alpha-
subunit and varying degrees of homology in their beta-sub-
units. There is considerable homology between the beta-sub-
units of hCG and TSH. As a result, hCG has weak thyroid-
stimulating activity and may cause thyrotoxicosis during the
period of highest serum hCG concentrations (peaks at 10–12
weeks’ gestation). The range of hCG at peak is wide with
values between 20 000–150 000 mIU/ml noted at the end of
the first trimester. The thyroid stimulating effect of 1 mIU/ml
of hCG is equivalent to 0.0013 mIU/l of TSH. Prolonged and sig-
nificant elevation of hCG (usually more than 200 000 mIU/ml) is
thus required to increase thyroid hormone production and
cause clinical effects.5
Hyperemesis gravidarum is associated with higher levels of hCG
and thus a potential cause of hCG-mediated thyrotoxicosis. It
has also been proposed that the biological activity of the hCG
found in patients with HG, specifically in terms of TSH receptor
interaction, is enhanced.6,7 Trophoblastic thyrotoxicosis and the
rare entity of familial gestational thyrotoxicosis, due to a mutant
TSH receptor that is hypersensitive for physiological hCG levels,
represent the other forms of hCG-mediated thyrotoxicosis.
The transient thyrotoxicosis of HG must be distinguished from
thyrotoxicosis of other non-pregnancy-related causes. In repro-
ductive-aged females it is most likely Graves’ disease. The
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presence of vomiting, the absence of goitre and ophthalmopa-
thy, and the absence of a tachycardia greater than 100 beats/
minute help to clinically differentiate. If Graves’ disease is sus-
pected, TSH-receptor antibodies should be tested and are posi-
tive in more than 90% of cases.8 Furthermore, persistence of
functional thyroid abnormalities beyond the first trimester of
normal pregnancies is probably not hCG-mediated and also
argues for exclusion of non-pregnancy-related causes such as
Graves’ disease.9
In view of the well-known association of HG with abnormal
thyroid functions, many centres, including ours, routinely evalu-
ate thyroid function as part of their work-up in women admitted
for HG. Thyroid function is not done selectively based on a clini-
cal concern of thyrotoxicosis. The thyroid abnormalities associ-
ated with HG are described in the literature as mild in nature
and usually do not require therapy per se.10,11
Current treatment and management of HG includes resuscita-
tion, identification and treatment of the cause of vomiting, cor-
rection of electrolyte imbalances, symptomatic support such as
rehydration, anti-emetics, thiamine supplementation and nutri-
tional as well as psychological support.12
With this study we sought to determine the prevalence and
aetiology of thyrotoxicosis in women who presented with HG
to Tygerberg Hospital’s Obstetrics and Gynaecology Depart-
ment over a time period of 44 months. The research will
explore the contribution of a clinical evaluation to differentiate
Graves’ disease from the other aetiologies of thyrotoxicosis, will
document the course of hCG-mediated thyroid dysfunction in
the absence of thyroid pathology and evaluate the ideal
timing of thyroid function testing in patients presenting with
severe nausea and clinical dehydration in pregnancy. This
may allow cost reduction in laboratory testing, shortened in-
hospital stay and prevention of inappropriate thyroid-specific
interventions.
Materials and methods
Design and study population
A descriptive study based on retrospective data collection was
performed at Tygerberg Hospital (TH), affiliated to Stellenbosch
University. All women who presented from August 2016 until
April 2019 with HG or severe vomiting requiring admission to
Tygerberg Hospital were considered for inclusion into the
study. Patients were admitted for stabilisation and intravenous
fluids and assessed by the responsible medical teams to have
HG. It is standard practice in the Obstetrics Department of
Tygerberg Hospital to routinely perform serum hCG and to do
thyroid function testing on all patients with HG (TSH and fT4)
on admission. Patients for whom baseline hCG measurements
and thyroid function test results were not available were
excluded from the analysis. Informed consent was waived due
to the retrospective nature of data collection. The study com-
plied with the World Medical Association Declaration of Helsinki
and was approved and registered by the Human Research and
Ethics Committee at the Faculty of Medicine and Health
Sciences, Stellenbosch University, South Africa (HEA-2018-
8742).
Data collection
Patient clinical information and data were retrieved from the
Tygerberg Electronic Content Management System (ECM) and
biochemical results obtained via the National Health Laboratory
System (NHLS) electronic platform. Strict confidentiality was
maintained as the ECM and NHLS databases, as well as personal
computers used for data collection, are password protected and
therefore restrict access to data. Patient information and data
were entered onto a spreadsheet using Excel version 2016
Microsoft Office Professional Plus (Microsoft Corp, Redmond,
WA, USA). A unique number was linked to each patient’s data
set and the patient de-identified.
Demographics
Demographic data pertaining to maternal age, parity, gesta-
tional age at presentation, prior history or family history of
thyroid disorders or hyperemesis gravidarum and human
immunodeficiency virus (HIV) status if known were collected.
Biochemistry
Laboratory data collected included baseline hCG and thyroid
function tests (TSH and fT4). Available data on follow-up
thyroid function tests, at discharge and after 20 weeks of ges-
tation, as well as TSH receptor antibody status, were also
recorded.
Serum TSH, free T4 (fT4) and free T3 (fT3) in this study were
measured on the Roche Cobas e 601 analyser (Roche Diagnos-
tics, Mannheim, Germany). A competition principle immunoas-
say is used for the determination of free thyroxine fT4 and fT3
and results determined via a calibration curve. The measuring
ranges for fT4 and fT3 are 0.3–100 pmol/l and 0.3–10 nmol/l
and the normal reference intervals are 12–22 pmol/l and 3.1–
6.8 nmol/l respectively. A non-competitive sandwich immu-
noassay is applied for TSH with the same principle as for fT3
and fT4. The TSH measuring range is 0.005–100 μIU/ml with a
normal reference interval of 0.27–4.2 mIU/l. The local NHLS
does not report trimester-specific normal ranges. The inter-
assay coefficient of variance at various clinically significant
cut-off points for serum TSH, fT4 and fT3 was less than 3%.
At baseline, a diagnosis of thyrotoxicosis was made in the pres-
ence of a suppressed TSH level based on the NHLS laboratory
reference range and a concomitant increase in circulating
levels of fT4 and/or fT3. Ideally TSH levels in pregnancy
should be defined by population-based normative data in
iodine-replete women. Globally the use of trimester-specific
TSH ranges is advocated in in the absence of population-
based reference data in view of the known lowering of both
the lower and upper range of TSH, especially in the latter part
of the first trimester (weeks 7–12). A TSH range of 0.1–
2.5 mIU/l and a TSH range of 0.2–3 mIU/l are globally regarded
as acceptable to apply for the first and second trimester of preg-
nancy in the absence of available population-based reference
values.11 Although we categorised patients as thyrotoxic or
euthyroid based on the non-adjusted NHLS-TSH range, the
impact of using trimester-specific TSH on the categorisation of
women as thyrotoxic will be reflected on.
The iodine status of patients is not routinely assessed in this
specific cohort and is a limitation of the current study.
TSH-receptor antibodies were measured using an electrochemi-
luminescence immunoassay (ECLIA) with the Cobas e immu-
noassay analysers. Results are determined via a calibration
curve.13 The normal reference interval in the NHLS laboratory
is a value less than 1.00 U/l and a value above this is regarded
as positive. Additional antibody testing was not done to
confirm the underlying aetiology of thyrotoxicosis.
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presence of vomiting, the absence of goitre and ophthalmopa-
thy, and the absence of a tachycardia greater than 100 beats/
minute help to clinically differentiate. If Graves’ disease is sus-
pected, TSH-receptor antibodies should be tested and are posi-
tive in more than 90% of cases.8 Furthermore, persistence of
functional thyroid abnormalities beyond the first trimester of
normal pregnancies is probably not hCG-mediated and also
argues for exclusion of non-pregnancy-related causes such as
Graves’ disease.9
In view of the well-known association of HG with abnormal
thyroid functions, many centres, including ours, routinely evalu-
ate thyroid function as part of their work-up in women admitted
for HG. Thyroid function is not done selectively based on a clini-
cal concern of thyrotoxicosis. The thyroid abnormalities associ-
ated with HG are described in the literature as mild in nature
and usually do not require therapy per se.10,11
Current treatment and management of HG includes resuscita-
tion, identification and treatment of the cause of vomiting, cor-
rection of electrolyte imbalances, symptomatic support such as
rehydration, anti-emetics, thiamine supplementation and nutri-
tional as well as psychological support.12
With this study we sought to determine the prevalence and
aetiology of thyrotoxicosis in women who presented with HG
to Tygerberg Hospital’s Obstetrics and Gynaecology Depart-
ment over a time period of 44 months. The research will
explore the contribution of a clinical evaluation to differentiate
Graves’ disease from the other aetiologies of thyrotoxicosis, will
document the course of hCG-mediated thyroid dysfunction in
the absence of thyroid pathology and evaluate the ideal
timing of thyroid function testing in patients presenting with
severe nausea and clinical dehydration in pregnancy. This
may allow cost reduction in laboratory testing, shortened in-
hospital stay and prevention of inappropriate thyroid-specific
interventions.
Materials and methods
Design and study population
A descriptive study based on retrospective data collection was
performed at Tygerberg Hospital (TH), affiliated to Stellenbosch
University. All women who presented from August 2016 until
April 2019 with HG or severe vomiting requiring admission to
Tygerberg Hospital were considered for inclusion into the
study. Patients were admitted for stabilisation and intravenous
fluids and assessed by the responsible medical teams to have
HG. It is standard practice in the Obstetrics Department of
Tygerberg Hospital to routinely perform serum hCG and to do
thyroid function testing on all patients with HG (TSH and fT4)
on admission. Patients for whom baseline hCG measurements
and thyroid function test results were not available were
excluded from the analysis. Informed consent was waived due
to the retrospective nature of data collection. The study com-
plied with the World Medical Association Declaration of Helsinki
and was approved and registered by the Human Research and
Ethics Committee at the Faculty of Medicine and Health
Sciences, Stellenbosch University, South Africa (HEA-2018-
8742).
Data collection
Patient clinical information and data were retrieved from the
Tygerberg Electronic Content Management System (ECM) and
biochemical results obtained via the National Health Laboratory
System (NHLS) electronic platform. Strict confidentiality was
maintained as the ECM and NHLS databases, as well as personal
computers used for data collection, are password protected and
therefore restrict access to data. Patient information and data
were entered onto a spreadsheet using Excel version 2016
Microsoft Office Professional Plus (Microsoft Corp, Redmond,
WA, USA). A unique number was linked to each patient’s data
set and the patient de-identified.
Demographics
Demographic data pertaining to maternal age, parity, gesta-
tional age at presentation, prior history or family history of
thyroid disorders or hyperemesis gravidarum and human
immunodeficiency virus (HIV) status if known were collected.
Biochemistry
Laboratory data collected included baseline hCG and thyroid
function tests (TSH and fT4). Available data on follow-up
thyroid function tests, at discharge and after 20 weeks of ges-
tation, as well as TSH receptor antibody status, were also
recorded.
Serum TSH, free T4 (fT4) and free T3 (fT3) in this study were
measured on the Roche Cobas e 601 analyser (Roche Diagnos-
tics, Mannheim, Germany). A competition principle immunoas-
say is used for the determination of free thyroxine fT4 and fT3
and results determined via a calibration curve. The measuring
ranges for fT4 and fT3 are 0.3–100 pmol/l and 0.3–10 nmol/l
and the normal reference intervals are 12–22 pmol/l and 3.1–
6.8 nmol/l respectively. A non-competitive sandwich immu-
noassay is applied for TSH with the same principle as for fT3
and fT4. The TSH measuring range is 0.005–100 μIU/ml with a
normal reference interval of 0.27–4.2 mIU/l. The local NHLS
does not report trimester-specific normal ranges. The inter-
assay coefficient of variance at various clinically significant
cut-off points for serum TSH, fT4 and fT3 was less than 3%.
At baseline, a diagnosis of thyrotoxicosis was made in the pres-
ence of a suppressed TSH level based on the NHLS laboratory
reference range and a concomitant increase in circulating
levels of fT4 and/or fT3. Ideally TSH levels in pregnancy
should be defined by population-based normative data in
iodine-replete women. Globally the use of trimester-specific
TSH ranges is advocated in in the absence of population-
based reference data in view of the known lowering of both
the lower and upper range of TSH, especially in the latter part
of the first trimester (weeks 7–12). A TSH range of 0.1–
2.5 mIU/l and a TSH range of 0.2–3 mIU/l are globally regarded
as acceptable to apply for the first and second trimester of preg-
nancy in the absence of available population-based reference
values.11 Although we categorised patients as thyrotoxic or
euthyroid based on the non-adjusted NHLS-TSH range, the
impact of using trimester-specific TSH on the categorisation of
women as thyrotoxic will be reflected on.
The iodine status of patients is not routinely assessed in this
specific cohort and is a limitation of the current study.
TSH-receptor antibodies were measured using an electrochemi-
luminescence immunoassay (ECLIA) with the Cobas e immu-
noassay analysers. Results are determined via a calibration
curve.13 The normal reference interval in the NHLS laboratory
is a value less than 1.00 U/l and a value above this is regarded
as positive. Additional antibody testing was not done to
confirm the underlying aetiology of thyrotoxicosis.
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Serum from clotted blood was used for intact hCG measure-
ment by means of a sandwich immunometric assay.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (8.2.0)
(https://www.graphpad.com/scientific-software/prism/). The
normal distribution of data was determined using the
Shapiro–Wilk and Kolmogorov–Smirnov tests. Data are pre-
sented as either mean ± standard deviation (SD) (normal distri-
bution) or median (interquartile range) (IQR) (non-parametric
data). Student’s t-test with two-tailed p-value and non-para-
metric Mann–Whitney tests were performed to determine
differences between the thyrotoxic and euthyroid cohorts.
The Kruskal–Wallis multiple comparisons test was used to deter-
mine differences between the hCG-mediated and Graves’ dis-
eases and molar pregnancy cohorts. Level of significance was
accepted at p < 0.05.
Results
Demographic characteristics of the participants
The demographics of the total study cohort, the thyrotoxic
cohort and the euthyroid cohort are summarised in Table 1.
Demographics and thyroid status of the total study
cohort with HG
A total of 82 women with HG who underwent thyroid function
testing were included in the study cohort. Almost half of
women (40/82 [49%]) with HG were thyrotoxic at baseline.
Seven women had suppressed but measurable TSH levels
with normal circulating fT4 and fT3 in keeping with subclinical
thyrotoxicosis. These women were classified within the euthyr-
oid group and not regarded as having overt thyroid disease.
The mean age of the total study population was 26.4 ± 5.3 years
and the age ranged between 16 and 41 years. Three-quarters
(60/82 [73%]) were multigravidas, median gestation at presen-
tation was 11 (IQR 8–14) weeks and the majority (54/82
[66%]) presented with HG in the first trimester of pregnancy.
Only three women presented with HG after 18 weeks’ gestation,
two of whom had abnormal (molar) pregnancies. Multiple preg-
nancies were documented in only 4/82 (5%) and abnormal
(molar) pregnancies were present in 9/82 (11%) women. The
majority of women had testing for HIV (73/82 [95%]) – only 4/
73 tested positive (5% of total study cohort).
Five women (5/82 [6%]) reported known prior thyroid disease.
Clinical features of Graves’ disease at presentation (presence
of diffusely enlarged goitre with or without bruit and/or extra-
thyroidal features including thyroid eye disease and/or pretibial
myxoedema) was only present in four women; one of these
women had known Graves’ prior to the index pregnancy.
Demographics of the thyrotoxic and euthyroid study
cohorts with HG
The demographic characteristics of the thyrotoxic (40/82) and
euthyroid cohorts (42/82) were similar (Table 1). Similar age,
ethnicity, parity, total number of first trimester presentations,
pregnancy subtypes and HIV status were noted. Abnormal
(molar) pregnancies occurred in both cohorts. Clinical features
of Graves’ disease were present in a small minority of women
within the thyrotoxic group (4 [10%]).
Biochemical characteristics of the total study cohort
with HG
Biochemistry at baseline in the women with and without thyro-
toxicosis is depicted in Table 2. The median hCG level in the
thyrotoxic cohort (195 431 mIU/ml [IQR134 733–334 871]) was
significantly (p < 0.001) higher compared with the euthyroid
Table 1: Demographic characteristics of total, thyrotoxic and euthyroid cohorts with HG
Description Total cohort (n = 82) Thyrotoxic cohort (n = 40) Euthyroid cohort (n = 42)
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Prior thyroid disease 5 (6%) 5 (13%) 0 (0%)
Clinical features of Graves’ disease 4 (5%) 4 (10%) n/a
Thyrotoxic cohort defined as patients with suppressed TSH according to local laboratory reference range in the presence of elevated circulating free T4 ± elevated free T3.
Data expressed as n (%) except for age and duration of gestation which are expressed as mean ± SDa and median (25%−75% IQR)b respectively.*Denominator refers to
multigravidas only. Statistical analysis: Student’s t-test with two-tailed p-valuea and non-parametric Mann–Whitney testb. No statistical differences were evident between
the thyrotoxic and euthyroid cohorts.
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group (75 670 mIU/ml [IQR33 652–193 688]), but with extreme
ranges. A significant overlap is present between measured hCG
levels in those with thyrotoxicosis (40/82) compared with
euthyroid (42/82) women with no clear upper cut-off level to
identify those at risk of elevated thyroid function (Figure 1).
The median fT4 in the thyrotoxic cohort (40/82) was 33.6 pmol/l
(IQR25.1–45.1), with the mean (39.2 pmol/l) near twice the
upper limit of normal (ULN) of 22 pmol/l. Free T4 values at base-
line ranged from 14.7 pmol/l to values 4.5x the ULN at
100 pmol/l, in 22/40 (55%) women with thyrotoxicosis fT4
values were more than 1.5 times the upper range of normal.
The fT3 was performed in 15/40 women with thyrotoxicosis,
with a median value of 12 nmol/L (IQR10.5–19) and the mean
(15.5 nmol/l) more than twice the ULN for the local NHLS labora-
tory (6.8 nmol/l). In 10 of 15 women tested, the fT3 was more
than 1.5 times the ULN.
The local NHLS laboratory report a normal TSH range irre-
spective of the duration of pregnancy. Application of globally
accepted trimester-specific TSH ranges impacted minimally
on classification of functional thyroid status in our cohort.
In women with overt thyrotoxicosis, i.e. suppressed TSH
values based on NHLS range and elevated circulating fT4,
only one woman re-classified as being euthyroid based on a
normal trimester-specific TSH. Three of the seven women
with subclinical hyperthyroidism within the euthyroid
cohort still fulfilled criteria for TSH suppression after correc-
tion based on trimester-specific TSH range. None of the
women with HG had biochemical evidence of overt primary
hypothyroidism.
Testing for TSH-receptor antibodies was performed in 23/40
(58%) women with a biochemical diagnosis of thyrotoxicosis
and noted to be positive in 5/23 women. Antibody testing
was performed in three of the four women who presented
with clinical features suggestive of Graves’ disease and was
noted to be positive in all except one.
Biochemical characteristics in the thyrotoxic cohort
within different aetiological subgroups
Graves’ disease was confirmed to be the underlying aetiology in
6/40 women. Molar pregnancies were present in 5/40 of the
thyrotoxic women and in 29/40 women the thyrotoxicosis
was the result of hCG-mediated gestational thyrotoxicosis.
The diagnosis of Graves’ disease was based on clinical features
and positive antibodies in three (3/6) women, clinical features
only in one (1/6) woman and a positive antibody test in two
(2/6) women in the absence of a clinical suspicion of Graves’.
Molar pregnancy was the cause of the clinical presentation
with HG in 9/82 women with associated thyrotoxicosis docu-
mented in 5/9 (56%).
The comparative baseline biochemistry of women with hCG-
mediated thyrotoxicosis versus those with Graves’ disease and
underlying trophoblastic disease (molar pregnancy) is noted
in Table 3. A significant difference in fT4 at diagnosis was only
evident between women with hCG-mediated thyrotoxicosis
and those with underlying molar pregnancies (p = 0.036). The
extent of elevation of thyroid function tests in women with
hCG-mediated thyrotoxicosis (29/40) varied significantly with
the highest recordable fT4 value 100 pmol/l and the lowest
value 14.7 pmol/l, the highest fT3 46.7 nmol/l and the lowest
value 4.7 nmol/l (Table 3). In the 29/40 women, 12/29 women
had a fT4 value elevated to more than 1.5x ULN of the labora-
tory and in 7/29 (24%) women the fT4 level exceeded
40 pmol/l. Likewise fT3 values ranged between a highest
value of 46.7 nmol/l and lowest value of 4.7 nmol/l with
values exceeding 1.5x ULN in 3/8 (38%) women in whom fT3
was assessed.
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FT4a (pmol/l) 33.6 (25.1–45.1) 18.1 (15.2–21)
FT3a (nmol/l)(n = 15) 12 (10.5–19) 5.2 (5.1–5.4)
TSH receptor antibody
Measured n = 23 n/a
Positive 5 n/a
Thyrotoxic cohort defined as patients with suppressed TSH according to local lab-
oratory reference range and elevated circulating free T4 ± elevated free T3.
Cohort size as noted in heading unless otherwise specified. Data are expressed
as either n (%), absolute values or median (25%−75% IQR)a. Statistical analysis:
non-parametric Mann–Whitney test a. *p < 0.01 indicates significant difference
between the thyrotoxic and euthyroid cohorts. Adjusted rangeb refer to globally
accepted trimester-specific TSH ranges (trimester 1: 0.1–2.5 mIU/l; trimester 2:
0.2–3.0 mIU/l). n/a = not applicable. Normal range fT4 = 12–22 pmol/l and
normal range fT3 = 3.1–6.8 pmol/l.
Figure 1: hCG at baseline in the women with and without thyrotoxi-
cosis. Individual values are presented with the median indicated (solid
line) for the thyrotoxic (n = 40) and euthyroid (n = 42) cohorts. Statistical
analysis: Mann–Whitney test.
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group (75 670 mIU/ml [IQR33 652–193 688]), but with extreme
ranges. A significant overlap is present between measured hCG
levels in those with thyrotoxicosis (40/82) compared with
euthyroid (42/82) women with no clear upper cut-off level to
identify those at risk of elevated thyroid function (Figure 1).
The median fT4 in the thyrotoxic cohort (40/82) was 33.6 pmol/l
(IQR25.1–45.1), with the mean (39.2 pmol/l) near twice the
upper limit of normal (ULN) of 22 pmol/l. Free T4 values at base-
line ranged from 14.7 pmol/l to values 4.5x the ULN at
100 pmol/l, in 22/40 (55%) women with thyrotoxicosis fT4
values were more than 1.5 times the upper range of normal.
The fT3 was performed in 15/40 women with thyrotoxicosis,
with a median value of 12 nmol/L (IQR10.5–19) and the mean
(15.5 nmol/l) more than twice the ULN for the local NHLS labora-
tory (6.8 nmol/l). In 10 of 15 women tested, the fT3 was more
than 1.5 times the ULN.
The local NHLS laboratory report a normal TSH range irre-
spective of the duration of pregnancy. Application of globally
accepted trimester-specific TSH ranges impacted minimally
on classification of functional thyroid status in our cohort.
In women with overt thyrotoxicosis, i.e. suppressed TSH
values based on NHLS range and elevated circulating fT4,
only one woman re-classified as being euthyroid based on a
normal trimester-specific TSH. Three of the seven women
with subclinical hyperthyroidism within the euthyroid
cohort still fulfilled criteria for TSH suppression after correc-
tion based on trimester-specific TSH range. None of the
women with HG had biochemical evidence of overt primary
hypothyroidism.
Testing for TSH-receptor antibodies was performed in 23/40
(58%) women with a biochemical diagnosis of thyrotoxicosis
and noted to be positive in 5/23 women. Antibody testing
was performed in three of the four women who presented
with clinical features suggestive of Graves’ disease and was
noted to be positive in all except one.
Biochemical characteristics in the thyrotoxic cohort
within different aetiological subgroups
Graves’ disease was confirmed to be the underlying aetiology in
6/40 women. Molar pregnancies were present in 5/40 of the
thyrotoxic women and in 29/40 women the thyrotoxicosis
was the result of hCG-mediated gestational thyrotoxicosis.
The diagnosis of Graves’ disease was based on clinical features
and positive antibodies in three (3/6) women, clinical features
only in one (1/6) woman and a positive antibody test in two
(2/6) women in the absence of a clinical suspicion of Graves’.
Molar pregnancy was the cause of the clinical presentation
with HG in 9/82 women with associated thyrotoxicosis docu-
mented in 5/9 (56%).
The comparative baseline biochemistry of women with hCG-
mediated thyrotoxicosis versus those with Graves’ disease and
underlying trophoblastic disease (molar pregnancy) is noted
in Table 3. A significant difference in fT4 at diagnosis was only
evident between women with hCG-mediated thyrotoxicosis
and those with underlying molar pregnancies (p = 0.036). The
extent of elevation of thyroid function tests in women with
hCG-mediated thyrotoxicosis (29/40) varied significantly with
the highest recordable fT4 value 100 pmol/l and the lowest
value 14.7 pmol/l, the highest fT3 46.7 nmol/l and the lowest
value 4.7 nmol/l (Table 3). In the 29/40 women, 12/29 women
had a fT4 value elevated to more than 1.5x ULN of the labora-
tory and in 7/29 (24%) women the fT4 level exceeded
40 pmol/l. Likewise fT3 values ranged between a highest
value of 46.7 nmol/l and lowest value of 4.7 nmol/l with
values exceeding 1.5x ULN in 3/8 (38%) women in whom fT3
was assessed.
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FT4a (pmol/l) 33.6 (25.1–45.1) 18.1 (15.2–21)
FT3a (nmol/l)(n = 15) 12 (10.5–19) 5.2 (5.1–5.4)
TSH receptor antibody
Measured n = 23 n/a
Positive 5 n/a
Thyrotoxic cohort defined as patients with suppressed TSH according to local lab-
oratory reference range and elevated circulating free T4 ± elevated free T3.
Cohort size as noted in heading unless otherwise specified. Data are expressed
as either n (%), absolute values or median (25%−75% IQR)a. Statistical analysis:
non-parametric Mann–Whitney test a. *p < 0.01 indicates significant difference
between the thyrotoxic and euthyroid cohorts. Adjusted rangeb refer to globally
accepted trimester-specific TSH ranges (trimester 1: 0.1–2.5 mIU/l; trimester 2:
0.2–3.0 mIU/l). n/a = not applicable. Normal range fT4 = 12–22 pmol/l and
normal range fT3 = 3.1–6.8 pmol/l.
Figure 1: hCG at baseline in the women with and without thyrotoxi-
cosis. Individual values are presented with the median indicated (solid
line) for the thyrotoxic (n = 40) and euthyroid (n = 42) cohorts. Statistical
analysis: Mann–Whitney test.
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Course of hCG-mediated thyrotoxicosis in women with
HG
The course of hCG-mediated thyrotoxicosis (29/40) was docu-
mented for the women with thyrotoxicosis at baseline who
had follow-up assessment of fT4 prior to discharge (19/29)
and later in gestation (13/29) as given in Table 4. The time inter-
val from admission to discharge in these women ranged from
two to seven days. Women were only treated for the HG and
received no thyroid-specific therapy or intervention. Follow-
up biochemistry in later gestation was recorded in 13/19
women with hCG-mediated thyrotoxicosis who also had
thyroid function done at baseline and on discharge at a mean
gestation of 17.4 ± 6 weeks. A significant spontaneous decline
in fT4 values was observed from day of admission to a later
stage in gestation (p < 0.001). Despite a decline already
evident from admission to discharge, this did not reach signifi-
cance (p = 0.286) (Figure 2A). A slight non-significant (p = 0.056)
decline in fT3 values was also evident from day of admission to
the later stage in pregnancy (Figure 2B).
Patients presenting with HG to Tygerberg Hospital, after resol-
ution of the nausea and vomiting, are sent back to their respect-
ive primary or secondary referral centres for further
management of the pregnancy. Available data pertaining to
the pregnancy outcome in women with hCG-mediated thyro-
toxicosis were limited and unknown in 17/29 women. Where
birth data were available, live births were noted in 8/12 (67%)
and a miscarriage/intrauterine death (IUDs) in four women
with hCG-mediated thyrotoxicosis. In the women with normal
thyroid function, birth data were unavailable in 18/41 women,
13 had live births (72%), four had either a miscarriage or IUD
(22%) and one had a termination of pregnancy for unknown
reason.
Discussion
In this study looking at thyroid status in women presenting
with HG, nearly half of the cohort (49%) were thyrotoxic at
baseline. In the vast majority of these women, the cause of
thyrotoxicosis was hCG-mediated without any other cause
present (72.5%). Graves’ disease was identified as the under-
lying cause in six (15%) and an underlying molar pregnancy in
five women (12.5%). Median fT4 levels were significantly
higher in the thyrotoxic cohort with underlying molar preg-
nancy compared with the hCG-mediated subgroup only
(p = 0.035), but a significant overlap in measured fT4 levels
was, however, present amongst the different aetiological sub-
groups with no clear upper level fT4 able to distinguish any of
the subgroups from one another. Extreme individual
elevation in fT4 was also noted in women with hCG-mediated
thyrotoxicosis; in seven women (24%) the fT4 value exceeded
40 pmol/l.
Table 3: Biochemistry at baseline in women with thyrotoxicosis (n = 40)
Description hCG-mediated (n = 29) Graves’ disease (n = 6) Molar pregnancy (n = 5) p-value




194 282 (114 032–260 312)
466 261
10 000
187 327 (119 805–401 329)
840 400
4 459
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Cohort size as noted in heading unless otherwise specified. Data are expressed as either n (%), absolute values or median (25%−75% IQR)a. Statistical analysis: Kruskal–Wallis
multiple comparisons test. #p < 0.05 indicates significant difference between the hCG-mediated (n = 29) and molar pregnancy cohorts (n = 5). No difference was evident
between hCG-mediated vs. Graves’ disease cohorts or the molar pregnancy vs. Graves’ disease cohorts. Adjusted rangeb refers to globally accepted trimester-specific TSH
ranges (trimester 1: 0.1–2.5 mIU/l; trimester 2: 0.2–3.0 mIU/lb; n.s. = not significant.). Normal range fT4 = 12–22 pmol/l and normal range fT3 = 3.1–6.8 pmol/l.
Table 4: Course of hCG-mediated thyrotoxicosis in women with HG on no thyroid treatment
Description (t1) on admission
(t2) on discharge
(2–7 days post admission)
(t3) later in gestation
(mean 17.4 ± 6 weeks) p-value
Thyroid function tests



























Data are expressed as either absolute values or median (25%−75% IQR)a. Statistical analysis: Kruskal–Wallis multiple comparisons test. #p < 0.05 indicates significant differ-
ence between values at admission and later in gestation.
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Hyperemesis gravidarum typically presents in the latter part of
the first trimester, at a time when hCG, regarded as the main
driver behind the extreme nausea and vomiting, is expected
to be highest.14 In addition, not only have higher circulating
levels of intact hCG been noted, but it has also been reported
that the form of hCG with increased affinity for the TSH receptor
containing additional asialo-carbohydrate chains is increased in
HG.6, 7
Our patients with HG and thyrotoxicosis presented at a median
gestation of 12 weeks (IQR 10–14). The majority of the thyro-
toxic cohort was represented by women with hCG-mediated
TSH receptor stimulation with underlying normal pregnancies.
The median hCG value noted in these women (Graves’ and
molar pregnancy excluded) was significantly higher than our
euthyroid HG cohort and vastly exceeds the normal range for
circulating intact hCG in the background population based on
gestational age.15,16 In a large prospective population-based
cohort from the Netherlands (n = 8 065 women), the normal
reference range coinciding with the median gestation at pres-
entation of our patients is 42 267 mIU/ml with a maximum
recorded value of 144 054 mIU/ml; these values are markedly
lower than the median hCG of 194 282 mIU/ml and maximum
recorded value of 466 261 mIU/ml noted in our hCG-mediated
thyrotoxic cohort and also lower than the median and
maximum value observed in the euthyroid women.15 We did
not evaluate different isoforms or subtypes of hCG in our
study cohort, but our work corroborates findings from other
studies supporting the notion that the degree of elevated
hCG determines the development of biochemical thyrotoxicosis
in HG.14, 17–19
The prevalence of thyrotoxicosis in our cohort of women with
HG was high, involved almost half of all women (49%) and in
the majority was attributed to hCG-mediated thyrotoxicosis
(72.7%). All women regarded as thyrotoxic had a suppressed
TSH value based on the local laboratory non-pregnancy range
and concomitant increased fT4 values. Ideally, population-
based trimester-specific reference ranges for TSH should be
used and defined through assessment of local population
data in iodine-replete pregnant women.20 It is recommended
globally to use adjusted trimester-specific TSH ranges in the
absence of locally available population data. Controversy
remains as to exactly how to adjust given significant geographic
and ethnic diversity, and also due to differences in laboratory
methodology. Adjustment of TSH assessment based on globally
accepted first and second trimester lower limits of normal, i.e.
TSH values < 0.1 mIU/l and <0.2 mIU/l respectively, had very
limited impact on categorisation in our patient cohort and
resulted in a single patient re-categorised as euthyroid. The
prevalence of thyrotoxicosis noted in our study is compar-
able to other published studies in the literature reporting
that as many as 60% of women with HG exhibit thyrotoxi-
cosis.14,16 In a retrospective study looking at 143 women
with HG, Sun et al.21 reported an incidence of thyrotoxicosis
in 48.3% of their cohort, a finding almost identical to ours.
Similarly, the vast majority of thyrotoxic women had hCG-
mediated thyrotoxicosis without underlying thyroid pathol-
ogy (65/69; 95%). In a prospective observational study by
Tan et al., 53 of 87 women (61%) with HG presented with
associated thyrotoxicosis and 44 were followed into later ges-
tation. Only five patients in their cohort had underlying
Graves’ disease.18
In view of the well-known association between HG and
thyrotoxicosis, it is standard practice in our institution to
request evaluation of thyroid function on admission in all
women with HG irrespective of the degree of TSH suppres-
sion. Testing for TSH-receptor antibodies is recommended in
patients in whom the fT4 levels are elevated based on our
NHLS laboratory range, but this recommendation is unfortu-
nately not always adhered to. This is in line with the
Endocrine Society Clinical Practice Guideline (2012) that rec-
ommends thyroid function and thyroid receptor antibodies
be done in all patients with HG and biochemical evidence
of thyrotoxicosis.22
The more recent updated guidelines from the American Thyroid
Association (ATA) in 2017 recommend that fT4 should be done
only if the TSH is suppressed < 0.1 mIU/ml, but do not propose
Figure 2: Course of hCG-mediated thyrotoxicosis in women with HG.
Individual values are presented with the median indicated (solid line)
for (A) fT4 and (B) fT3. Statistical analysis: Kruskal–Wallis multiple com-
parisons test. t1 = day of admission; t2 = day of discharge; t3 = later
stage in gestation.
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NHLS laboratory range, but this recommendation is unfortu-
nately not always adhered to. This is in line with the
Endocrine Society Clinical Practice Guideline (2012) that rec-
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specific timing with regard to testing in women with HG. The
updated guidelines also recommend TSH-receptor antibody
testing only if the aetiology remains unclear after a careful clini-
cal assessment.20
Interestingly, if clinicians abided by the 2017 updated rec-
ommendations of the ATA, all thyrotoxic patients with Graves’
in whom a TSH value was available (5/6), 2 of the 5 women
with molar pregnancy and 10 of the 29 women (34%) with
hCG-mediated thyrotoxicosis qualified for fT4 testing. In the
six women with hCG-mediated thyrotoxicosis in whom fT4
values were available at (t3), a TSH suppressed to below detect-
able limits (< 0.01 mIU/ml) did not signify unsuspected thyroid
disease or the need for specific antithyroid therapy. Spon-
taneous resolution of elevated thyroid function without any
thyroid intervention was noted in 5/6 women and fT4 remained
only marginally elevated at 22.4 pmol/l (normal range up to
22 pmol/l) in one patient.
It is uncertain to what degree dehydration, with associated
hypovolemia and haemoconcentration, at the time of admis-
sion in women with HG influences measures of both fT4 and
fT3. Very little has been reported in the literature on this
topic. In a single study, dehydration has been shown to pro-
foundly affect total serum thyroid hormone concentrations
due to changes in thyroid hormone-binding proteins, but also
documented volume depletion to result in the elevation of
free thyroxine. These elevations reverse acutely upon rehydra-
tion, in parallel with the decrease in extra-cellular fluid
volume status markers.16 In clinical practice, we have had
similar experiences in that the abnormal thyroid biochemistry
improves significantly and even normalises on adequate rehy-
dration during hospitalisation. These high values may, in inex-
perienced hands, result in antithyroid therapy that may not
be warranted and may not be in the patient’s best interest.
Based on median fT4 values, a decline was observed in our
patient group with hCG-mediated thyrotoxicosis from baseline
(t1) to both later time points (t2 and t3), reaching significance
only at (t3) (p < 0.001). With the exception of a single individual
with a baseline minimal increase in fT4, a decline in fT4 was
noted in all women from baseline to discharge (average time
interval 2–5 days). The most overt decline, interestingly, was
noted in those with extreme elevations (baseline >4 0 pmol/l)
with an average decline of 26.7 pmol/l (range of decline 14.5–
56.1 pmol/l). This raises the question as to the possible contri-
bution of dehydration to measured values and the validity of
measured free thyroid hormones at the time of volume
depletion.
Few studies have been published in the literature looking at the
course of hCG-mediated thyrotoxicosis into later gestation.
Based on reported data, hCG-mediated thyrotoxicosis is
expected to resolve at a time when circulating hCG-levels
decline, i.e. from the 15th week of gestation onwards.3,17,18 In
a study by Sun and colleagues, a gradual decline in fT4 levels
was noted one and two months after presentation with HG
and thyrotoxicosis in all patients without any specific antithyr-
oid intervention;21 similarly Tan and co-workers documented
normalisation in their thyrotoxic cohort in the middle of the
second trimester without any antithyroid medication.18 In our
study a significant decline in fT4 was observed at (t3) from base-
line assessment (p < 0.001); the timing of the follow-up assess-
ment was, however, not standardised, but performed at a
median of 17.4 weeks. In 8 of the 13 women in whom a
follow-up fT4 was available, values normalised completely on
follow-up, while in the remaining 5 slightly elevated fT4 was
still present (none more than 1.5 times the upper limit of
normal). In four of the five women with elevated fT4, the
follow-up was done at 13–15 weeks’ gestation – a time point
earlier than noted for normalisation in other published work.
The association between HG and thyrotoxicosis in other sub-
Saharan populations has not been studied to date.
Although Graves’ disease is responsible for the minority of cases
with thyrotoxicosis in the setting of HG as noted in our study (6/
40 [15%]) and in other published work (5/53 [9.4%]) in a study
conducted by Tan et al.18, and in 4/69 (5.8%) women in the
study by Sun et al.21, it is the commonest non-pregnancy
related inherent thyroid condition responsible for thyrotoxicosis
in reproductive-aged women and must not be overlooked.
Graves’ should be considered in any women with HG presenting
with overt diffuse goitre (with or without an audible bruit), the
presence of extra-thyroidal features such as thyroid orbitopathy
or rarely with pretibial myxoedema and evidence of adrenergic
overactivity, and can be confirmed with antibody testing. Care
must, however, be taken not to over-interpret an appropriately
increased pulse rate in the presence of significant dehydration.
Tachycardia must thus be evaluated along with the rest of the
patient’s clinical presentation. Clinical features were not univer-
sally present in all women with Graves’ disease in our study: in
2/6 (33.3%) of our Graves’ cohort the diagnosis was based on
antibody testing without clinical suspicion.
It has been suggested by some studies and even by the ATA
that fT4 and especially fT3 is higher in women with Graves’
disease compared with hCG-mediated thyrotoxicosis of HG,
last mentioned as a result of the auto-immune process on the
thyroid with increased intrathyroidal T3 production.23 Higher
hCG values have also been documented in those with hCG-
mediated thyrotoxicosis compared with Graves’ in women
with HG.17 This was not confirmed in our study at baseline
assessment. There was a tendency for higher median fT4 and
fT3 levels in the Graves’ cohort, but these did not reach statisti-
cal significance. Interestingly, TSH values were noted to be
unrecordable in all women with Graves’ disease, but this was
noted in only 34% of those with hCG-mediated thyrotoxicosis.
This may indicate a longer period of sustained thyroid excess
in women with Graves’ and again raises the question as to
the temporary effect of dehydration on measured thyroid
hormone levels at the time of admission. Median hCG values
were comparable in the two thyrotoxic groups.
The study had limitations. The retrospective nature of the study
resulted in a lack of standardisation of treatment protocols and
impacted on optimal timing and completeness of follow-up bio-
chemistry. Trimester-specific TSH rangeswere not used to define
the thyrotoxic cohort and although the local TSH reference range
correctly categorised 39 of the 40 thyrotoxic patients, future
work in pregnancy should adhere to global recommendations.
The study population was small and only 47.5% and 32.5% of
the thyrotoxic cohort returned for follow-up assessment at (t2)
and (t3) respectively. TSH receptor antibody testing was done
in only half of the thyrotoxic women and could have been
more easily regulated with a prospective study design.
Conclusion
Thyrotoxicosis is common in women presenting with HG and
affects nearly half of all cases, with hCG-mediated thyrotoxicosis
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the commonest aetiology. The fT4 values decreased with clini-
cal stabilisation of HG, suggesting a possible contribution of
dehydration to the large variation in baseline fT4 measurements
noted. A future prospective study is, however, required to
confirm this observation. Consideration should be given to
postponing testing for thyroid overactivity until adequate rehy-
dration has been ensured. The distinction between hCG-
mediated thyrotoxicosis and Graves’ disease is not always
easy. A low threshold for TSH-receptor antibody testing
should be maintained, especially in women with TSH <
0.01 mIU/l and in those with persistent fT4 elevation on dis-
charge and later in gestation. Final review of thyroid function
in women with HG should be standardised and ideally per-
formed after 15 weeks’ gestation.
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